255th ENMC workshop: Muscle imaging in idiopathic inflammatory myopathies. 15th January, 16th January and 22nd January 2021 - virtual meeting and hybrid meeting on 9th and 19th September 2022 in Hoofddorp, The Netherlands

Marianne de Visser; Pierre Carlier; Jiří Vencovský; Kateřina Kubínová; Corinna Preusse; ENMC Muscle Imaging in Idiopathic Inflammatory Myopathies workshop study group

doi:10.1016/j.nmd.2023.08.014

255th ENMC workshop: Muscle imaging in idiopathic inflammatory myopathies. 15th January, 16th January and 22nd January 2021 - virtual meeting and hybrid meeting on 9th and 19th September 2022 in Hoofddorp, The Netherlands

Neuromuscul Disord. 2023 Oct;33(10):800-816. doi: 10.1016/j.nmd.2023.08.014. Epub 2023 Sep 3.

Authors

Marianne de Visser¹, Pierre Carlier², Jiří Vencovský³, Kateřina Kubínová³, Corinna Preusse⁴; ENMC Muscle Imaging in Idiopathic Inflammatory Myopathies workshop study group

Collaborators

ENMC Muscle Imaging in Idiopathic Inflammatory Myopathies workshop study group:
Jemima Albayda⁵, Yves Allenbach⁶, Olivier Benveniste⁶, Pierre Carlier⁷, Louise Diederichsen⁸, Georges Demonceau⁹, Ingrid de Groot¹⁰, Anneke van der Kooi¹¹, Kateřina Kubínová¹², Pedro Machado¹³, Andrew Mammen¹⁴, Harmen Reyngoudt¹⁵, Roland Mischke¹⁶, Jasper Morrow¹⁷, Nicoló Pipitone¹⁸, Corinna Preusse¹⁹, Michael Rataj²⁰, Lisa Rider²¹, Jens Schmidt²², Werner Stenzel²³, Giorgio Tasca²⁴, Jiří Vencovský²⁵, Marianne de Visser¹¹, Camiel Verhamme¹¹

Affiliations

¹ Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centre, Location Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: m.devisser@amsterdamumc.nl.
² CEA, Orsay, Paris, France.
³ Institute of Rheumatology, Department of Rheumatology, Charles University, Prague, Czech Republic.
⁴ Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health Department of Neuropathology, Berlin, Germany.
⁵ Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
⁶ Department of Internal Medicine and Clinical Immunology, Center of Research in Myology, Sorbonne University, Paris, France.
⁷ radiologist, CEA, Orsay, Paris, France.
⁸ Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
⁹ Dept. of Nuclear Medicine, CHBA, Liège, Belgique.
¹⁰ The Netherlands, patient representative.
¹¹ Department of Neurology, Amsterdam University Medical Centre, location Academic Medical Centre, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
¹² early career researcher, Institute of Rheumatology, Department of Rheumatology, 1(st) Medical Faculty, Charles University, Prague, Czech Republic.
¹³ Department of Neuromuscular Diseases, UCL Queen Square Insitute of Neurology & Centre for Rheumatology, Division of Medicine, University College London (UCL), London, UK.
¹⁴ Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
¹⁵ Institute of Myology, Neuromuscular Investigation Center, NMR Laboratory, Paris, France.
¹⁶ Germany, patient representative.
¹⁷ neurologist, Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK.
¹⁸ Rheumatology Unit, Department of Internal Medicine, Reggio Emilia, Italy.
¹⁹ early career researcher, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health Department of Neuropathology, Berlin, Germany.
²⁰ Polen, patient representative.
²¹ Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, Maryland, USA.
²² Department of Neurology and Pain Treatment, Neuromuscular Center, Center for Translational Medicine, Immanuel Klinik Rüdersdorf, University Hospital of the Brandenburg Medical School, 15562 Rüdersdorf bei Berlin; Department of Neuropathology, University Medical Center Göttingen, 37075 Göttingen, Germany.
²³ Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health Department of Neuropathology, Berlin, Germany.
²⁴ neurologist, John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trusts, Newcastle upon Tyne, UK; UOC di Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
²⁵ rheumatologist, Institute of Rheumatology, Department of Rheumatology, 1(st) Medical Faculty, Charles University, Prague, Czech Republic.

PMID: 37770338
DOI: 10.1016/j.nmd.2023.08.014

Abstract

The 255th ENMC workshop on Muscle Imaging in Idiopathic Inflammatory myopathies (IIM) aimed at defining recommendations concerning the applicability of muscle imaging in IIM. The workshop comprised of clinicians, researchers and people living with myositis. We aimed to achieve consensus on the following topics: a standardized protocol for the evaluation of muscle images in various types of IIMs; the exact parameters, anatomical localizations and magnetic resonance imaging (MRI) techniques; ultrasound as assessment tool in IIM; assessment methods; the pattern of muscle involvement in IIM subtypes; the application of MRI as biomarker in follow-up studies and clinical trials, and the place of MRI in the evaluation of swallowing difficulty and cardiac manifestations. The following recommendations were formulated: In patients with suspected IIM, muscle imaging is highly recommended to be part of the initial diagnostic workup and baseline assessment. MRI is the preferred imaging modality due to its sensitivity to both oedema and fat accumulation. Ultrasound may be used for suspected IBM. Repeat imaging should be considered if patients do not respond to treatment, if there is ongoing diagnostic uncertainty or there is clinical or laboratory evidence of disease relapse. Quantitative MRI is established as a sensitive biomarker in IBM and could be included as a primary or secondary outcome measure in early phase clinical trials, or as a secondary outcome measure in late phase clinical trials. Finally, a research agenda was drawn up.

Publication types

Clinical Conference

MeSH terms

Biomarkers
Humans
Magnetic Resonance Imaging / methods
Muscle, Skeletal / pathology
Myositis* / diagnosis
Netherlands

Substances

Biomarkers